Free Trial
→ This stock has 30 days of quiet left (From Behind the Markets) (Ad)tc pixel Free BRTX Stock Alerts

Biorestorative Therapies (BRTX) Competitors

Biorestorative Therapies logo
$0.21 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$0.21 +0.01 (+2.88%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BRTX vs. BMGL, ACON, MGRX, MRAI, and ADVB

Should you buy Biorestorative Therapies stock or one of its competitors? MarketBeat compares Biorestorative Therapies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biorestorative Therapies include Basel Medical Group (BMGL), Aclarion (ACON), Mangoceuticals (MGRX), Marpai (MRAI), and Advanced Biomed (ADVB). These companies are all part of the "healthcare" industry.

How does Biorestorative Therapies compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

69.4% of Biorestorative Therapies shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Basel Medical Group had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 1 mentions for Basel Medical Group and 0 mentions for Biorestorative Therapies. Basel Medical Group's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score.

Company Overall Sentiment
Basel Medical Group Neutral
Biorestorative Therapies Neutral

Basel Medical Group has higher revenue and earnings than Biorestorative Therapies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Basel Medical Group$8.90M1.26-$9.50MN/AN/A
Biorestorative Therapies$360K14.72-$14.24M-$1.07N/A

Basel Medical Group has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Basel Medical Group's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Basel Medical GroupN/A N/A N/A
Biorestorative Therapies -3,088.27%-508.42%-230.94%

Basel Medical Group has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Basel Medical Group beats Biorestorative Therapies on 6 of the 10 factors compared between the two stocks.

How does Biorestorative Therapies compare to Aclarion?

Biorestorative Therapies (NASDAQ:BRTX) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Biorestorative Therapies has a net margin of -3,088.27% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,088.27% -508.42% -230.94%
Aclarion -10,320.51%-54.41%-51.71%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aclarion
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 0.8% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biorestorative Therapies has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

In the previous week, Aclarion's average media sentiment score of 1.00 beat Biorestorative Therapies' score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company Overall Sentiment
Biorestorative Therapies Neutral
Aclarion Positive

Aclarion has lower revenue, but higher earnings than Biorestorative Therapies. Aclarion is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$360K14.72-$14.24M-$1.07N/A
Aclarion$80K98.71-$7.23M-$9.03N/A

Summary

Biorestorative Therapies and Aclarion tied by winning 6 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Mangoceuticals?

Biorestorative Therapies (NASDAQ:BRTX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Biorestorative Therapies has higher earnings, but lower revenue than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$360K14.72-$14.24M-$1.07N/A
Mangoceuticals$460K16.83-$20.64M-$1.49N/A

Biorestorative Therapies has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Biorestorative Therapies has a net margin of -3,088.27% compared to Mangoceuticals' net margin of -4,639.13%. Mangoceuticals' return on equity of -112.00% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,088.27% -508.42% -230.94%
Mangoceuticals -4,639.13%-112.00%-104.96%

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Mangoceuticals had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 1 mentions for Mangoceuticals and 0 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.00 beat Mangoceuticals' score of -0.32 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company Overall Sentiment
Biorestorative Therapies Neutral
Mangoceuticals Neutral

Summary

Mangoceuticals beats Biorestorative Therapies on 7 of the 13 factors compared between the two stocks.

How does Biorestorative Therapies compare to Marpai?

Biorestorative Therapies (NASDAQ:BRTX) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Marpai
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Marpai has a net margin of -85.70% compared to Biorestorative Therapies' net margin of -3,088.27%. Marpai's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,088.27% -508.42% -230.94%
Marpai -85.70%N/A -100.23%

In the previous week, Biorestorative Therapies' average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company Overall Sentiment
Biorestorative Therapies Neutral
Marpai Neutral

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Biorestorative Therapies has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$360K14.72-$14.24M-$1.07N/A
Marpai$34.87M0.20-$28.75M-$0.87N/A

Biorestorative Therapies has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Marpai has a beta of 4.38, suggesting that its stock price is 338% more volatile than the broader market.

Summary

Marpai beats Biorestorative Therapies on 8 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Advanced Biomed?

Biorestorative Therapies (NASDAQ:BRTX) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

69.4% of Biorestorative Therapies shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by insiders. Comparatively, 34.4% of Advanced Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Advanced Biomed has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Advanced Biomed's return on equity of 87.74% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,088.27% -508.42% -230.94%
Advanced Biomed N/A 87.74%64.49%

In the previous week, Biorestorative Therapies' average media sentiment score of 0.00 equaled Advanced Biomed'saverage media sentiment score.

Company Overall Sentiment
Biorestorative Therapies Neutral
Advanced Biomed Neutral

Biorestorative Therapies has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Advanced Biomed has lower revenue, but higher earnings than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$360K14.72-$14.24M-$1.07N/A
Advanced BiomedN/AN/A-$3.26M$4.820.82

Summary

Advanced Biomed beats Biorestorative Therapies on 8 of the 10 factors compared between the two stocks.

Get Biorestorative Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for BRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BRTX vs. The Competition

Export
MetricBiorestorative TherapiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.30M$3.37B$6.46B$12.34B
Dividend YieldN/A2.26%2.76%5.28%
P/E Ratio-0.1918.7421.2125.65
Price / Sales14.72323.98554.3886.31
Price / CashN/A125.1743.4956.67
Price / Book1.737.0910.377.14
Net Income-$14.24M$24.45M$3.57B$335.98M
7 Day Performance13.29%6.38%6.40%4.15%
1 Month Performance-9.53%2.43%3.53%2.54%
1 Year Performance-87.47%62.98%34.04%35.06%

Biorestorative Therapies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BRTX
Biorestorative Therapies
0.4706 of 5 stars		$0.21
flat		N/A-87.5%$5.30M$360KN/A7
BMGL
Basel Medical Group
0.141 of 5 stars		$0.63
-4.6%		N/A-56.4%$11.78M$8.90MN/A36
ACON
Aclarion
1.1742 of 5 stars		$3.19
-0.3%		N/A-52.1%$7.85M$80KN/A7
MGRX
Mangoceuticals
1.0181 of 5 stars		$0.43
+3.4%		N/A-73.3%$7.25M$460KN/A3
MRAI
Marpai
N/A$0.26
-2.9%		N/A-79.9%$6.64M$34.87MN/A150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BRTX) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel